Hodgkin lymphoma: The follow-up of long-term survivors

Hodgkin lymphoma (HL) is a disease that typically strikes children and young adults, with more than 80% of those affected being cured. Consequently, HL survivors can five for decades with the persistent and late-emerging effects of the disease and its treatment. The focus of this article is the long-term medical management of HL survivors, specifically those who are 5 years or more off therapy without evidence of relapse, when the focus of follow-up care shifts from detecting relapse to minimizing the morbidity associated with the late effects of treatment.